%0 Journal Article
%T The role of VI-RADS scoring criteria for predicting oncological outcomes in bladder cancer.
%A Kozikowski M
%A Zagrodzka M
%A Zawadzki M
%A Zugaj P
%A Osiecki R
%A Rzymkowski F
%A Śledź M
%A Sosnowski R
%A Dobruch J
%A Giudice FD
%A Krajewski W
%J World J Urol
%V 42
%N 1
%D 2024 Jul 24
%M 39046595
%F 3.661
%R 10.1007/s00345-024-05101-2
%X <B>OBJECTIVE: </B>Our purpose was to evaluate the prognostic value of Vesical Imaging Reporting and Data System (VI-RADS) in bladder cancer (BCa) staging and predicting recurrence or progression.<BR><B>METHODS: </B>We retrospectively analyzed the prospectively collected data from 96 patients with bladder tumors who underwent VI-RADS-based multiparametric magnetic resonance imaging (mpMRI) before endourological treatment from April 2021 to December 2022. Diagnostic performance was evaluated by comparing mpMRI reports with final pathology, using logistic regression for muscle-invasive bladder cancer (MIBC) predictors. Follow-up until May 2023 included Kaplan-Meier and Cox regression analysis to assess VI-RADS predictive roles for recurrence-free survival (RFS) and progression-free survival (PFS).<BR><B>RESULTS: </B>A total of 96 patients (19.8% women, 80.2% men; median age 68.0 years) were included, with 71% having primary tumors and 29% recurrent BCa. Multiparametric MRI exhibited high sensitivity (92%) and specificity (79%) in predicting MIBC, showing no significant differences between primary and recurrent cancers (AUC: 0.96 vs. 0.92, P = .565). VI-RADS emerged as a key predictor for MIBC in both univariate (OR: 40.3, P < .001) and multivariate (OR: 54.6, P < .001) analyses. Primary tumors with VI-RADS ≥ 3 demonstrated significantly shorter RFS (P = .02) and PFS (P = .04).<BR><B>CONCLUSIONS: </B>In conclusion, mpMRI with VI-RADS has a high diagnostic value in predicting MIBC in both primary and recurrent BCa. A VI-RADS threshold ≥ 3 is a strong predictor for MIBC, and in primary tumors predicts early recurrence and progression.